This variability may reflect the heterogeneous nature of autoantibodies targeting GPIb/V/IX, GPIIb/IIIa and other platelet-related antigens. In addition to direct pathogenic effects of antibodies ...

C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment. Receive the the latest news, research, and presentations from major meetings ...

The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.

Modern dosing of bivalirudin was evaluated in the REPLACE-2 trial, which randomized 6010 patients undergoing elective or urgent PCI [7] to UFH with planned GPIIb/IIIa or bivalirudin with ...